

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 June 2020 (11.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/117373 A8

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 9/19 (2006.01)
A61K 9/08 (2006.01) C07K 16/28 (2006.01)

SUN, Yingqing; 11296 Laurelcres Drive, San Diego, CA 92130 (US). VAN SCHRAVENDIJK, Marie Rose; 6401 Sand Point Way NE, Seattle, WA 98115 (US).

(21) International Application Number:

PCT/US2019/056214

(74) Agent: MILLER, Elizabeth Cary et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(22) International Filing Date:

15 October 2019 (15.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/774,819 03 December 2018 (03.12.2018) US

(71) Applicants: AGENSYS, INC. [US/US]; 1800 Stewart Street, Santa Monica, CA 90404 (US). SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, WA 98021 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(72) Inventors: MCGARVEY, Orla; Lonza AG, Hochbergerstrasse 60 A, 4057 Basel (CH). RATNASWAMY, Gayathri; 16811 Magnolia Boulevard, Encino, CA 91436 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-19IP4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF




FIG. 1A

(57) Abstract: A pharmaceutical composition comprising an antibody drug conjugate comprising an antibody or antigen binding fragment thereof that binds to 19IP4D12 conjugated to one or more units of monomethyl auri statin E (MMAE) and a pharmaceutically acceptable excipient comprising L-histidine, polysorbate-20 (TWEEN-20), and at least one of trehalose dihydrate and sucrose.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

18 February 2021 (18.02.2021)

(15) Information about Correction:

see Notice of 18 February 2021 (18.02.2021)